Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pyruvate

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    104 result(s) found for: Pyruvate. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2021-003265-36 Sponsor Protocol Number: AG348-C-022 Start Date*: 2022-05-10
    Sponsor Name:Agios Pharmaceuticals, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Subjects With Pyruvate Kinase Deficiency Who Are Regularly T...
    Medical condition: Pyruvate Kinase Deficiency
    Disease: Version SOC Term Classification Code Term Level
    21.1 10010331 - Congenital, familial and genetic disorders 10037682 Pyruvate kinase deficiency anaemia PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) CZ (Ongoing) DK (Ongoing) IT (Prematurely Ended) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001031-72 Sponsor Protocol Number: HP-POST-COVID Start Date*: 2021-04-08
    Sponsor Name:Aarhus University, The MR Research Center
    Full Title: Metabolic MRI with hyperpolarized pyruvate in long-term COVID19 patients
    Medical condition: Long-term COVID19 symptoms
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084382 Coronavirus disease 2019 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000310-15 Sponsor Protocol Number: HC-MRI-GBM Start Date*: 2020-03-26
    Sponsor Name:Christoffer Laustsen
    Full Title: MRI WITH HYPERPOLARISED PYRUVATE IN GLIOBLASTOMA – A PHASE II STUDY
    Medical condition: Glioblastoma multiforme
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003459-39 Sponsor Protocol Number: AG348-C-011 Start Date*: 2019-04-10
    Sponsor Name:Agios Pharmaceuticals, Inc.
    Full Title: An Open-Label, Multicenter, Extension Study of AG-348 in Adult Subjects with Pyruvate Kinase Deficiency Previously Enrolled in AG-348 Studies
    Medical condition: Pyruvate Kinase Deficiency Haemolytic anaemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10010331 - Congenital, familial and genetic disorders 10037682 Pyruvate kinase deficiency anaemia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) FR (Ongoing) IE (Ongoing) NL (Ongoing) DE (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-003333-11 Sponsor Protocol Number: AG348-C-023 Start Date*: 2022-04-25
    Sponsor Name:Agios Pharmaceuticals, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Subjects With Pyruvate Kinase Deficiency Who Are Not Regular...
    Medical condition: Pyruvate Kinase Deficiency
    Disease: Version SOC Term Classification Code Term Level
    21.1 10010331 - Congenital, familial and genetic disorders 10037682 Pyruvate kinase deficiency anaemia PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Ongoing) FR (Ongoing) IT (Ongoing) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000484-13 Sponsor Protocol Number: AG-348-C-003 Start Date*: 2015-07-10
    Sponsor Name:Agios Pharmaceuticals Inc
    Full Title: A Phase 2, Open Label, Randomized, Dose Ranging, Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of AG-348 in Adult Patients with Pyruvate Kinase Deficiency
    Medical condition: Pyruvate Kinase Deficiency
    Disease: Version SOC Term Classification Code Term Level
    21.1 10010331 - Congenital, familial and genetic disorders 10037682 Pyruvate kinase deficiency anaemia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Ongoing) NL (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003533-15 Sponsor Protocol Number: LIFE-04-CHF Start Date*: 2018-12-04
    Sponsor Name:Department of Cardiology, Aarhus University Hospital
    Full Title: Clinical and pathophysiological aspects of visualization of metabolic flux in the failing human heart using hyperpolarized [1-13C]-pyruvate cardiac magnetic resonance
    Medical condition: Chronic Heart Failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10007540 Cardiac disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000863-56 Sponsor Protocol Number: HP-HCC Start Date*: 2021-05-04
    Sponsor Name:Aarhus University, The MR Research Center
    Full Title: Early detection of hepatocellular carcinoma by Hyperpolarized [1-13C]pyruvate MRI
    Medical condition: Primary liver cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036706 Primary liver cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001550-34 Sponsor Protocol Number: TIGEM2-PDH Start Date*: Information not available in EudraCT
    Sponsor Name:FONDAZIONE TELETHON
    Full Title: Studio clinico pilota per valutare l’efficacia della terapia con fenilbutirrato in pazienti affetti da deficit di piruvato deidrogenasi
    Medical condition: La Sperimentazione verrà eseguita su pazienti affetti da difetto dell’enzima piruvato deidrogenasi.I pazienti affetti da questa malattia manifestano aumento dei livelli di lattato nel sangue e nell...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10058097 Metabolic disorder PT
    20.1 10027433 - Metabolism and nutrition disorders 10000491 Acidosis lactic LLT
    20.0 10022891 - Investigations 10037677 Pyruvate LLT
    20.0 10022891 - Investigations 10023660 Lactate increased LLT
    20.0 10022891 - Investigations 10057975 Lactate pyruvate ratio PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023878-40 Sponsor Protocol Number: 2.3 Start Date*: 2011-12-22
    Sponsor Name:Medical University Vienna
    Full Title: Influence of intra-arterial cerebral Papaverine Hydrochloride on cerebral glucose, lactate, pyruvate, glycerol, and glutamate concentrations, cerebral oxygenation, angiographic vasospasm, delayed s...
    Medical condition: To demonstrate the influence of intra-arterial cerebral Papaverine Hydrochloride on cerebral glucose, lactate, pyruvate, glycerol, and glutamate concentrations and cerebral oxygenation in patients ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003803-22 Sponsor Protocol Number: AG348-C-007 Start Date*: 2018-06-27
    Sponsor Name:Agios Pharmaceuticals, Inc.
    Full Title: An Open-Label Study to Evaluate the Efficacy and Safety of AG-348 in Regularly Transfused Adult Subjects With Pyruvate Kinase (PK) Deficiency
    Medical condition: Pyruvate Kinase Deficiency
    Disease: Version SOC Term Classification Code Term Level
    21.1 10010331 - Congenital, familial and genetic disorders 10037682 Pyruvate kinase deficiency anaemia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) DK (Completed) GB (Completed) IE (Completed) IT (Completed) ES (Prematurely Ended) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2019-001656-19 Sponsor Protocol Number: RP-L301-0119 Start Date*: 2019-09-19
    Sponsor Name:Rocket Pharmaceuticals, Inc.
    Full Title: Gene Therapy for Pyruvate Kinase Deficiency (PKD): A Phase I Clinical Trial to Evaluate the Safety of the Infusion of Autologous CD34+ Cells Transduced with a Lentiviral Vector Carrying the Codon O...
    Medical condition: Pyruvate kinase deficiency
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10037682 Pyruvate kinase deficiency anaemia PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004491-22 Sponsor Protocol Number: LIFE-PC-01 Start Date*: 2017-09-01
    Sponsor Name:Dept. Clinical Medicine, Aarhus Universit
    Full Title: Early detection of effects of chemotherapy in pancreatic cancer patients – a study using MR-hyperpolarization scanning based on hyperpolarized Pyruvate (13C) injection
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033575 Pancreas cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003823-31 Sponsor Protocol Number: AG348-C-006 Start Date*: 2019-04-08
    Sponsor Name:Agios Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Subjects With Pyruvate Kinase Deficiency
    Medical condition: Pyruvate Kinase Deficiency
    Disease: Version SOC Term Classification Code Term Level
    21.1 10010331 - Congenital, familial and genetic disorders 10037682 Pyruvate kinase deficiency anaemia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) FR (Completed) PT (Completed) ES (Completed) DK (Completed) NL (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000352-36 Sponsor Protocol Number: HP-ALS-TIA Start Date*: 2020-04-27
    Sponsor Name:Christoffer Laustsen
    Full Title: MRI of neurometabolic impairment in ALS and TIA using hyperpolarized pyruvate
    Medical condition: Amyotrophic lateral sclerosis Transient ischemic attack
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001656-35 Sponsor Protocol Number: LIFE-02-MF Start Date*: 2019-01-10
    Sponsor Name:Dept.Dermotology , Aarhus University
    Full Title: Metabolic imaging of patients with mycosis fungoides using hyperpolarized 13C-Pyruvate magnetic resonance imaging – A feasibility study
    Medical condition: mycosis fungiodes
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028483 Mycosis fungoides PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-003280-26 Sponsor Protocol Number: IMB101-005 Start Date*: 2020-11-09
    Sponsor Name:Imbria Pharmaceuticals, Inc.
    Full Title: A Dose-Ranging Pharmacodynamic Study to Evaluate the Effects of IMB-1018972 on Myocardial Energetics, Metabolism, and Function in Patients with Type 2 Diabetes
    Medical condition: Diabetic Cardiomyopathy (DbCM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10012647 Diabetic cardiomyopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-002216-14 Sponsor Protocol Number: 1277 Start Date*: 2017-07-26
    Sponsor Name:Clinical Pharmacology, MUV
    Full Title: Investigation of Pharmacokinetic of Antiinfective Therapy in Healthy Subjects and Severely Burned Patients Admitted to the ICU
    Medical condition: This is an exploratory pharmacokinetic trial in healthy volunteers (cohort A) and patients with severe burns admitted to the ICU (cohort B). The Information retrieved by these investigations will h...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-002551-11 Sponsor Protocol Number: HP-CKDPKD Start Date*: 2022-01-18
    Sponsor Name:Aarhus University
    Full Title: Chronic kidney disease – imaging the metabolic derangements with ultra-sensitive MRI
    Medical condition: Chronic kidney disease and polycystic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    20.0 10010331 - Congenital, familial and genetic disorders 10036046 Polycystic kidney, autosomal dominant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-000534-20 Sponsor Protocol Number: THAM05 Start Date*: 2005-03-15
    Sponsor Name:Addenbrooke's Hospital NHS Foundation Trust
    Full Title: Influence of brain tissue pH regulation on cerebral oxygenation and metabolism in patients with severe traumatic brain injury.
    Medical condition: Severe traumatic brain injury
    Disease:
    Population Age: Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 04:33:08 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA